Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer.

Chan J, Kinsella MT, Willis JE, Hu H, Reynolds H Jr, Delaney C, McCulla A, Deharo S, Ahdesmäki M, Allen WL, Johnston PG, Kinsella TJ.

Front Oncol. 2013 Nov 25;3:288. doi: 10.3389/fonc.2013.00288. eCollection 2013.


Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells.

Proutski I, Stevenson L, Allen WL, McCulla A, Boyer J, McLean EG, Longley DB, Johnston PG.

Mol Cancer Ther. 2009 Sep;8(9):2566-74. doi: 10.1158/1535-7163.MCT-09-0158. Epub 2009 Sep 1.


The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells.

Allen WL, McLean EG, Boyer J, McCulla A, Wilson PM, Coyle V, Longley DB, Casero RA Jr, Johnston PG.

Mol Cancer Ther. 2007 Jan;6(1):128-37.


Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.

Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG.

Cancer Res. 2006 Mar 1;66(5):2765-77.


Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.

Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG.

Clin Cancer Res. 2004 Mar 15;10(6):2158-67.


Dysfunction of p53 in photocarcinogenesis.

Gervin CM, McCulla A, Williams M, Ouhtit A.

Front Biosci. 2003 May 1;8:s715-7. Review.


Supplemental Content

Loading ...
Support Center